Loading…
Investigating Functional and Folding Stability of an Engineered E. coli L-asparaginase Harboring Y176F/S241C Mutations
Purpose: L-asparaginase has been widely recognized as a critical component in the treatment of various types of lymphoproliferative disorders, since its introduction in 1960s. However, its use in some cases leads to allergic reactions rendering the continuation of treatment unfeasible. Thus, the dev...
Saved in:
Published in: | Advanced pharmaceutical bulletin 2024-10, Vol.14 (3), p.675-685 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c302t-5f38f90087fddc3ef2cc1e0448463edd05c5e64bcc82dd8bc8193de06ed0c5473 |
container_end_page | 685 |
container_issue | 3 |
container_start_page | 675 |
container_title | Advanced pharmaceutical bulletin |
container_volume | 14 |
creator | Dastmalchi, Mahrokh Hamzeh-Mivehroud, Maryam Rezazadeh, Hassan Farajollahi, Mohammad M Dastmalchi, Siavoush |
description | Purpose: L-asparaginase has been widely recognized as a critical component in the treatment of various types of lymphoproliferative disorders, since its introduction in 1960s. However, its use in some cases leads to allergic reactions rendering the continuation of treatment unfeasible. Thus, the development of L-asparaginase from alternative sources or the production of engineered enzymes have always been considered. This study aimed to produce and evaluate a novel enzyme designed based on the sequence of L-asparaginase from Escherichia coli bacteria with Y176F/S241C mutations. Methods: The Y176F/S241C mutant L-asparaginase was successfully expressed as the GST-fusion protein in E. coli, and then was subjected to affinity and size exclusion chromatography. The activity of the purified enzyme was determined based on the released ammonia as the result of substrate hydrolysis using Nessler’s reagent. Chemical denaturation experiment in the presence of increasing concentration of guanidinium chloride was applied to determine the folding stability of the purified enzyme. Results: The mutant enzyme was purified with an efficiency of 77-fold but at a low recovery of 0.7%. The determined kinetic parameters Km, Vmax, kcat, specific activity and catalytic efficiency were 13.96 (mM), 2.218 (mM/min), 273.9 (min-1), 237.8 (IU/mg) and 19.62 (mM-1 min-1), respectively. Moreover, unfolding free energy determined by guanidinium chloride induced denaturation for mutated and commercial L-asparaginase enzymes were 8421 J/mol and 5274 J/mol, respectively. Conclusion: The mutant enzyme showed improved stability over the wild-type. Although the expression level and recovery were low, the mutant L-asparaginase demonstrated promising activity and stability, with potential clinical and industrial applications. |
doi_str_mv | 10.34172/apb.2024.048 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11530880</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3132153125</sourcerecordid><originalsourceid>FETCH-LOGICAL-c302t-5f38f90087fddc3ef2cc1e0448463edd05c5e64bcc82dd8bc8193de06ed0c5473</originalsourceid><addsrcrecordid>eNpVUc9LwzAYLaLgmDt6D3hul19ts5PI2Nxg4mF68BTSJK2RLqlJO9h_b-qG4Ckfee973_e9lyT3CGaEohLPRVdlGGKaQcqukgnGOUpLAtn1WGOW5oyh22QWgqkgpSVmaIEmyXFrjzr0phG9sQ1YD1b2xlnRAmEVWLtWjd_7XlSmNf0JuDoCYGUbY7X2WoFVBqRrDdilInTCiwiIoMFG-Mr5sfcDlcV6vscULcHL0ItRPtwlN7Vog55d3mnyvl69LTfp7vV5u3zapZJA3Kd5TVi9gJCVtVKS6BpLiXRcn9GCaKVgLnNd0EpKhpVilYxHEaVhoRWUOS3JNHk863ZDddBKatt70fLOm4PwJ-6E4f8Raz55444coTx6x2BUeLgoePc9RKv4lxt8NChwggiONITzyErPLOldCF7XfyMQ5L_58JgPH_PhMR_yA9y3hJE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3132153125</pqid></control><display><type>article</type><title>Investigating Functional and Folding Stability of an Engineered E. coli L-asparaginase Harboring Y176F/S241C Mutations</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Dastmalchi, Mahrokh ; Hamzeh-Mivehroud, Maryam ; Rezazadeh, Hassan ; Farajollahi, Mohammad M ; Dastmalchi, Siavoush</creator><creatorcontrib>Dastmalchi, Mahrokh ; Hamzeh-Mivehroud, Maryam ; Rezazadeh, Hassan ; Farajollahi, Mohammad M ; Dastmalchi, Siavoush</creatorcontrib><description>Purpose: L-asparaginase has been widely recognized as a critical component in the treatment of various types of lymphoproliferative disorders, since its introduction in 1960s. However, its use in some cases leads to allergic reactions rendering the continuation of treatment unfeasible. Thus, the development of L-asparaginase from alternative sources or the production of engineered enzymes have always been considered. This study aimed to produce and evaluate a novel enzyme designed based on the sequence of L-asparaginase from Escherichia coli bacteria with Y176F/S241C mutations. Methods: The Y176F/S241C mutant L-asparaginase was successfully expressed as the GST-fusion protein in E. coli, and then was subjected to affinity and size exclusion chromatography. The activity of the purified enzyme was determined based on the released ammonia as the result of substrate hydrolysis using Nessler’s reagent. Chemical denaturation experiment in the presence of increasing concentration of guanidinium chloride was applied to determine the folding stability of the purified enzyme. Results: The mutant enzyme was purified with an efficiency of 77-fold but at a low recovery of 0.7%. The determined kinetic parameters Km, Vmax, kcat, specific activity and catalytic efficiency were 13.96 (mM), 2.218 (mM/min), 273.9 (min-1), 237.8 (IU/mg) and 19.62 (mM-1 min-1), respectively. Moreover, unfolding free energy determined by guanidinium chloride induced denaturation for mutated and commercial L-asparaginase enzymes were 8421 J/mol and 5274 J/mol, respectively. Conclusion: The mutant enzyme showed improved stability over the wild-type. Although the expression level and recovery were low, the mutant L-asparaginase demonstrated promising activity and stability, with potential clinical and industrial applications.</description><identifier>ISSN: 2228-5881</identifier><identifier>EISSN: 2251-7308</identifier><identifier>DOI: 10.34172/apb.2024.048</identifier><language>eng</language><publisher>Tabriz: Tabriz University of Medical Sciences</publisher><subject>Apoptosis ; Cancer ; Cytotoxicity ; E coli ; Efficiency ; Enzymes ; Leukemia ; Microorganisms ; Mutation ; Original ; Plasmids ; Toxicity</subject><ispartof>Advanced pharmaceutical bulletin, 2024-10, Vol.14 (3), p.675-685</ispartof><rights>2024. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 The Author (s). 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c302t-5f38f90087fddc3ef2cc1e0448463edd05c5e64bcc82dd8bc8193de06ed0c5473</cites><orcidid>0000-0001-9427-0770 ; 0009-0003-2920-7750</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3132153125/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3132153125?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,44590,53791,53793,75126</link.rule.ids></links><search><creatorcontrib>Dastmalchi, Mahrokh</creatorcontrib><creatorcontrib>Hamzeh-Mivehroud, Maryam</creatorcontrib><creatorcontrib>Rezazadeh, Hassan</creatorcontrib><creatorcontrib>Farajollahi, Mohammad M</creatorcontrib><creatorcontrib>Dastmalchi, Siavoush</creatorcontrib><title>Investigating Functional and Folding Stability of an Engineered E. coli L-asparaginase Harboring Y176F/S241C Mutations</title><title>Advanced pharmaceutical bulletin</title><description>Purpose: L-asparaginase has been widely recognized as a critical component in the treatment of various types of lymphoproliferative disorders, since its introduction in 1960s. However, its use in some cases leads to allergic reactions rendering the continuation of treatment unfeasible. Thus, the development of L-asparaginase from alternative sources or the production of engineered enzymes have always been considered. This study aimed to produce and evaluate a novel enzyme designed based on the sequence of L-asparaginase from Escherichia coli bacteria with Y176F/S241C mutations. Methods: The Y176F/S241C mutant L-asparaginase was successfully expressed as the GST-fusion protein in E. coli, and then was subjected to affinity and size exclusion chromatography. The activity of the purified enzyme was determined based on the released ammonia as the result of substrate hydrolysis using Nessler’s reagent. Chemical denaturation experiment in the presence of increasing concentration of guanidinium chloride was applied to determine the folding stability of the purified enzyme. Results: The mutant enzyme was purified with an efficiency of 77-fold but at a low recovery of 0.7%. The determined kinetic parameters Km, Vmax, kcat, specific activity and catalytic efficiency were 13.96 (mM), 2.218 (mM/min), 273.9 (min-1), 237.8 (IU/mg) and 19.62 (mM-1 min-1), respectively. Moreover, unfolding free energy determined by guanidinium chloride induced denaturation for mutated and commercial L-asparaginase enzymes were 8421 J/mol and 5274 J/mol, respectively. Conclusion: The mutant enzyme showed improved stability over the wild-type. Although the expression level and recovery were low, the mutant L-asparaginase demonstrated promising activity and stability, with potential clinical and industrial applications.</description><subject>Apoptosis</subject><subject>Cancer</subject><subject>Cytotoxicity</subject><subject>E coli</subject><subject>Efficiency</subject><subject>Enzymes</subject><subject>Leukemia</subject><subject>Microorganisms</subject><subject>Mutation</subject><subject>Original</subject><subject>Plasmids</subject><subject>Toxicity</subject><issn>2228-5881</issn><issn>2251-7308</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpVUc9LwzAYLaLgmDt6D3hul19ts5PI2Nxg4mF68BTSJK2RLqlJO9h_b-qG4Ckfee973_e9lyT3CGaEohLPRVdlGGKaQcqukgnGOUpLAtn1WGOW5oyh22QWgqkgpSVmaIEmyXFrjzr0phG9sQ1YD1b2xlnRAmEVWLtWjd_7XlSmNf0JuDoCYGUbY7X2WoFVBqRrDdilInTCiwiIoMFG-Mr5sfcDlcV6vscULcHL0ItRPtwlN7Vog55d3mnyvl69LTfp7vV5u3zapZJA3Kd5TVi9gJCVtVKS6BpLiXRcn9GCaKVgLnNd0EpKhpVilYxHEaVhoRWUOS3JNHk863ZDddBKatt70fLOm4PwJ-6E4f8Raz55444coTx6x2BUeLgoePc9RKv4lxt8NChwggiONITzyErPLOldCF7XfyMQ5L_58JgPH_PhMR_yA9y3hJE</recordid><startdate>202410</startdate><enddate>202410</enddate><creator>Dastmalchi, Mahrokh</creator><creator>Hamzeh-Mivehroud, Maryam</creator><creator>Rezazadeh, Hassan</creator><creator>Farajollahi, Mohammad M</creator><creator>Dastmalchi, Siavoush</creator><general>Tabriz University of Medical Sciences</general><scope>AAYXX</scope><scope>CITATION</scope><scope>8AO</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9427-0770</orcidid><orcidid>https://orcid.org/0009-0003-2920-7750</orcidid></search><sort><creationdate>202410</creationdate><title>Investigating Functional and Folding Stability of an Engineered E. coli L-asparaginase Harboring Y176F/S241C Mutations</title><author>Dastmalchi, Mahrokh ; Hamzeh-Mivehroud, Maryam ; Rezazadeh, Hassan ; Farajollahi, Mohammad M ; Dastmalchi, Siavoush</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c302t-5f38f90087fddc3ef2cc1e0448463edd05c5e64bcc82dd8bc8193de06ed0c5473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Apoptosis</topic><topic>Cancer</topic><topic>Cytotoxicity</topic><topic>E coli</topic><topic>Efficiency</topic><topic>Enzymes</topic><topic>Leukemia</topic><topic>Microorganisms</topic><topic>Mutation</topic><topic>Original</topic><topic>Plasmids</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dastmalchi, Mahrokh</creatorcontrib><creatorcontrib>Hamzeh-Mivehroud, Maryam</creatorcontrib><creatorcontrib>Rezazadeh, Hassan</creatorcontrib><creatorcontrib>Farajollahi, Mohammad M</creatorcontrib><creatorcontrib>Dastmalchi, Siavoush</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Advanced pharmaceutical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dastmalchi, Mahrokh</au><au>Hamzeh-Mivehroud, Maryam</au><au>Rezazadeh, Hassan</au><au>Farajollahi, Mohammad M</au><au>Dastmalchi, Siavoush</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Investigating Functional and Folding Stability of an Engineered E. coli L-asparaginase Harboring Y176F/S241C Mutations</atitle><jtitle>Advanced pharmaceutical bulletin</jtitle><date>2024-10</date><risdate>2024</risdate><volume>14</volume><issue>3</issue><spage>675</spage><epage>685</epage><pages>675-685</pages><issn>2228-5881</issn><eissn>2251-7308</eissn><abstract>Purpose: L-asparaginase has been widely recognized as a critical component in the treatment of various types of lymphoproliferative disorders, since its introduction in 1960s. However, its use in some cases leads to allergic reactions rendering the continuation of treatment unfeasible. Thus, the development of L-asparaginase from alternative sources or the production of engineered enzymes have always been considered. This study aimed to produce and evaluate a novel enzyme designed based on the sequence of L-asparaginase from Escherichia coli bacteria with Y176F/S241C mutations. Methods: The Y176F/S241C mutant L-asparaginase was successfully expressed as the GST-fusion protein in E. coli, and then was subjected to affinity and size exclusion chromatography. The activity of the purified enzyme was determined based on the released ammonia as the result of substrate hydrolysis using Nessler’s reagent. Chemical denaturation experiment in the presence of increasing concentration of guanidinium chloride was applied to determine the folding stability of the purified enzyme. Results: The mutant enzyme was purified with an efficiency of 77-fold but at a low recovery of 0.7%. The determined kinetic parameters Km, Vmax, kcat, specific activity and catalytic efficiency were 13.96 (mM), 2.218 (mM/min), 273.9 (min-1), 237.8 (IU/mg) and 19.62 (mM-1 min-1), respectively. Moreover, unfolding free energy determined by guanidinium chloride induced denaturation for mutated and commercial L-asparaginase enzymes were 8421 J/mol and 5274 J/mol, respectively. Conclusion: The mutant enzyme showed improved stability over the wild-type. Although the expression level and recovery were low, the mutant L-asparaginase demonstrated promising activity and stability, with potential clinical and industrial applications.</abstract><cop>Tabriz</cop><pub>Tabriz University of Medical Sciences</pub><doi>10.34172/apb.2024.048</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-9427-0770</orcidid><orcidid>https://orcid.org/0009-0003-2920-7750</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2228-5881 |
ispartof | Advanced pharmaceutical bulletin, 2024-10, Vol.14 (3), p.675-685 |
issn | 2228-5881 2251-7308 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11530880 |
source | Publicly Available Content Database; PubMed Central |
subjects | Apoptosis Cancer Cytotoxicity E coli Efficiency Enzymes Leukemia Microorganisms Mutation Original Plasmids Toxicity |
title | Investigating Functional and Folding Stability of an Engineered E. coli L-asparaginase Harboring Y176F/S241C Mutations |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T21%3A41%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Investigating%20Functional%20and%20Folding%20Stability%20of%20an%20Engineered%20E.%20coli%20L-asparaginase%20Harboring%20Y176F/S241C%20Mutations&rft.jtitle=Advanced%20pharmaceutical%20bulletin&rft.au=Dastmalchi,%20Mahrokh&rft.date=2024-10&rft.volume=14&rft.issue=3&rft.spage=675&rft.epage=685&rft.pages=675-685&rft.issn=2228-5881&rft.eissn=2251-7308&rft_id=info:doi/10.34172/apb.2024.048&rft_dat=%3Cproquest_pubme%3E3132153125%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c302t-5f38f90087fddc3ef2cc1e0448463edd05c5e64bcc82dd8bc8193de06ed0c5473%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3132153125&rft_id=info:pmid/&rfr_iscdi=true |